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https://doi.org/10.1186/s12882-019-1251-zRESEARCH ARTICLE Open AccessPotential life-years gained over a 5-year
period by correcting DOPPS-identified
modifiable practices in haemodialysis: results
from the European MONITOR-CKD5 study
Christian Combe1, Johannes Mann2, David Goldsmith3, Frank Dellanna4, Philippe Zaoui5, Gérard London6,
Kris Denhaerynck7,8, Andriy Krendyukov9, Ivo Abraham7,10* and Karen MacDonald7Abstract
Background: DOPPS reported that thousands of life-years could be gained in the US and Europe over 5 years by
correcting six modifiable haemodialysis practices. We estimated potential life-years gained across 10 European
countries using MONITOR-CKD5 study data.
Methods: The DOPPS-based target ranges were used, except for haemoglobin due to label changes, as well as
DOPPS-derived relative mortality risks. Percentages of MONITOR-CKD5 patients outside targets were calculated.
Consistent with the DOPPS-based analyses, we extrapolated life-years gained for the MONITOR-CKD5 population
over 5 years if all patients were within targets.
Results: Bringing the 10 MONITOR-CKD5 countries’ dialysis populations into compliance on the six practices results
in a 5-year gain of 97,428 patient-years. In descending order, survival impact was the highest for albumin levels,
followed by phosphate levels, vascular access, haemoglobin, dialysis adequacy, and interdialytic weight gain.
Conclusions: Optimal management of the six modifiable haemodialysis practices may achieve 6.2% increase in
5-year survival.
Trial Registration: NCT01121237. Clinicaltrials.gov registration May 12, 2010 (retrospectively registered).
Keywords: Haemodialysis, Modifiable haemodialysis practices, Life-years, Biosimilar epoetin alfa, AnaemiaBackground
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) [1] reported [2] that an additional 143,617 pa-
tient life-years could be gained in the United States
over a 5-year period if six modifiable haemodialysis
practices were brought into best practice compliance.
Four of the six modifiable haemodialysis practices (dia-
lysis dose, phosphate control, improved anaemia, and
partial correction of serum albumin) are supported by
published guidelines [3–6] while reduced inter-dialytic
weight gain [7, 8] and reduced use of catheters for* Correspondence: iabraham@matrix45.com
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© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zevascular access [9–12] have been linked to mortality.
These analyses were replicated for Belgium [13], Spain
[14], France [15] and Sweden [16], except that albumin-
corrected serum calcium was substituted for intradialytic
weight gain. Here, we present a simulation of potential
life-years gained by correcting these six practices across
10 European countries using data from the MONITOR-
CKD5 study.
Methods
MONITOR-CKD5, a real-world, prospective, observa-
tional study on the treatment patterns and associated
outcomes of renal anaemia management with Sandoz
epoetin alfa biosimilar (commercially available as Bino-
crit®/Epoetin Alfa Hexal®; hereafter Binocrit®), included
an evaluable sample of 2023 CKD5 patients from 114le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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France (35), Germany (45), Italy (21), Poland (7),
Romania (14), Slovenia (2), Spain (6), Switzerland (4),
and the United Kingdom (4). Eligible were male or fe-
male CKD5 adult (age ≥ 18) patients on haemodialysis
of original or grafted kidneys; diagnosed with renal an-
aemia; and treated with intravenous Binocrit®. The
overall study methodology has been detailed elsewhere
[17]. The original DOPPS methodology to estimate
life-years gained from modifiable haemodialysis prac-
tices [2], as well as the methodology of the four country
replications [13–16] and the MONITOR-CKD5 ana-
lyses are summarized in Table 1.
Definition and Selection of Target Ranges for Modifiable
Practices
We used the same target ranges set forth in the 2004
DOPPS analysis [2] for dialysis dose (Kt/V ≥ 1.2), phos-
phate control (serum phosphate ≤5.5 mg/dL), and fluid
management (interdialytic weight gain ≤5.7%). For par-
tial correction of serum albumin, we applied the range
used in the Belgian [13], Spanish [14], and French [15]
replications (≥4.0 g/dL). Best practice guidelines for an-
aemia management have changed since 2004 with more
conservative haemoglobin targeting and individualized
risk-based dosing of erythropoiesis-stimulating agents [5,
18, 19]. Hence, the original [2] haemoglobin target of
≥11 g/dL was reduced to ≥10 g/dL in our analysis. For
the evaluation of catheter use for vascular access, all
DOPPS-based analyses [2, 13–16] used a facility-level
variable (percentage of catheter use at the centre-level).
In the MONITOR-CKD5 study, vascular access was not
collected as a facility-level but as a dichotomous patient-
level variable. Some centres contributed small numbers
of patients, hence determining centre percentages would
have been subject to bias.
Estimation of “Out of Range”
Table 2 presents the recommended targets for each
modifiable factor for the original DOPPS study [2] and
the replication studies [13–16] and the percentage of
each study sample outside the target range. We calcu-
lated the valid percentages of patients outside the indi-
cated range for the MONITOR-CKD5 evaluable sample
(n = 2023).
Selection of Mortality Relative Risk Values
In MONITOR-CKD5 patients were followed for up to
24 months, which is shorter than in DOPPS. Per expert
opinion, except for haemoglobin and catheter use, we
adopted the mortality RR values generated by the five
country-specific analyses (Table 2) [2, 13–16] based on
congruence in definition of target range between the
MONITOR-CKD5 and these studies, and similarities inpopulation. Due to guideline-recommended changes in
Hb targets since 2004, the RR of 1.22 associated with
Hb < 10 g/dL reported by Locatelli et al. was utilized
[20]. This is an estimate adjusted for age, gender, co-
morbidities, mobility, malnourishment, ability to eat
independently, years with end-stage renal disease
(ESRD), country, and facility. Since MONITOR-CKD5
study measured catheter use at the patient level, the
mortality RR adopted for this parameter was based on
findings from a patient-level analysis of mortality risk
associated with vascular access from DOPPS [21]; this
estimate was adjusted for age, gender, race, years with
ESRD, body weight, and comorbidities to reduce
treatment-by-indication bias.
Population Estimation
Haemodialysis prevalent and incident counts for the 10
countries in MONITOR-CKD5 are presented in Table 3.
Data for 7 of the 10 countries were obtained from the
2014 ERA-EDTA Registry Annual Report [22] Slovenia
was included in the 2013 [23] but not the 2014 ERA-
EDTA Report; hence, 2013 data were utilized. Neither
Germany nor Italy are included in the ERA-EDTA Regis-
try. The most recent and sufficiently detailed data from
their respective national databases were used instead,
which were 2006 data for Germany [24] and 2013 data for
Italy [25]. Country-level prevalent and incident counts
were extrapolated from year of data to 2017 using an an-
nual growth rate of 5%. However, this growth rate was not
included in the calculation of projected life-years over the
5 years, thus providing a conservative, lower-bound esti-
mation of life-years gained.* Patients younger than 20
years of age are not reported1 ERA-EDTA Registry:
Annual Report 2014 [22]2 Computed from 2006 dialysis
prevalence (808 pmp X 95.2%HD) and incidence (213
pmp X 92.6%HD) rates from Nierenersatztherapie in
Deutschland: Bericht über Dialysebehandlung und Nier-
entransplantation in Deutschland 2006–2007 [24] and
2006 population data (82,437,995) from Eurostat (http://
ec.europa.eu/eurostat/)3 Computed from 2013 dialysis
prevalence (760 pmp X 90.4%HD) and incidence (160 pmp
X 86.3%HD) rates from Registro Italiano Dialisi e Tra-
pianto: Report 2011–2013 [25] and 2013 population data
(59,685,227) from Eurostat (http://ec.europa.eu/eurostat/)4
Prevalent count from ERA-EDTA Registry 20141 (Section
B, aggregated data), incidence not reported; incident count
imputed as Poland’s HD prevalent count [19,345] X average
percentage of HD incident count/HD prevalent count of 9
countries with complete data [0.2044]5 ERA-EDTA Regis-
try: Annual Report 2013 [23]
Calculation of Attributable Patient-Years
We replicated the Port et al. [2] methodology for estimating
potential life-years gained using the MONITOR-CKD5
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Table 3 Haemodialysis prevalent and incident counts
Countries Source Year
of
Data
HD
Prevalent
Count
HD
Incident
Count
Extrapolation to 2017
HD Prevalent Count HD Incident Count
Austria ERA-EDTA Registry 20141 2014 3973 814 4599.24 942.31
France ° ERA-EDTA Registry 20141 2014 41,314 8321 47,826.12 9632.60
Germany Nierenersatztherapie in Deutschland
2006–20072
2006 63,413 16,260 108,457.11 27,809.96
Italy Registro Italiano di Dialisi e Trapianto
Report 2011–20133
2013 41,006 8241 49,843.22 10,017.40
Poland † ERA-EDTA Registry 20141 (Section B,
aggregated data)4
2014 19,345 3954 22,394.26 4577.25
Romania ^ ERA-EDTA Registry 20141 2014 14,686 2538 17,000.88 2938.05
Slovenia †† ERA-EDTA Registry 20135 2013 1349 209 1639.72 254.04
Spain ~ ERA-EDTA Registry 20141 2014 21,517 4236 24,908.62 4903.70
Switzerland ERA-EDTA Registry 20141 (Section B,
aggregated data)
2014 2636 663 3051.50 767.51
United Kingdom,
England only ° *
ERA-EDTA Registry 20141 2014 20,556 4107 23,796.14 4754.37
° Incident counts are estimated (see ERA-EDTA Registry: Annual Report 2014 for methods[22])
† Incidence data for Poland not reported; incident count imputed
^ Overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft
†† Slovenia not included in ERA-EDTA Registry 2014, so 2013 ERA-EDTA data used[23]
~ Counts for Spain are sums of the following:
Spain, Andalusia 4115 795
Spain, Aragon ° 529 105
Spain, Asturias ° 447 93
Spain, Basque country 789 159
Spain, Cantabria * 196 43
Spain, Castile & León °* 1078 217
Spain, Castile-La Mancha * 826 196
Spain, Catalonia ° 4227 889
Spain, Extremadura ° 590 106
Spain, Galicia 1540 292
Spain, Community of Madrid 2576 593
Spain, Region of Murcia 950 158
Spain, Navarre °* 251 61
Spain, Valencian region 3403 529
* Patients younger than 20 years of age are not reported
1 ERA-EDTA Registry: Annual Report 2014 [Ref 22]
2 Computed from 2006 dialysis prevalence (808 pmp X 95.2%HD) and incidence (213 pmp X 92.6%HD) rates from Nierenersatztherapie in Deutschland: Bericht über
Dialysebehandlung und Nierentransplantation in Deutschland 2006-2007 [Ref 24] and 2006 population data (82,437,995) from Eurostat (http://ec.europa.eu/eurostat/)
3 Computed from 2013 dialysis prevalence (760 pmp X 90.4%HD) and incidence (160 pmp X 86.3%HD) rates from Registro Italiano Dialisi e Trapianto: Report
2011-2013 [Ref 25] and 2013 population data (59,685,227) from Eurostat (http://ec.europa.eu/eurostat/)
4 Prevalent count from ERA-EDTA Registry 2014¹ (Section B, aggregated data), incidence not reported; incident count imputed as Poland's HD prevalent count
[19,345] X average percentage of HD incident count/HD prevalent count of 9 countries with complete data [0.2044]
5 ERA-EDTA Registry: Annual Report 2013 [Ref 23]
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current population statistics for the 10 countries in the
study, and the published relative risks associated with each
practice. Based on the estimated percentages of patients
falling outside the target ranges of the six modifiable prac-
tices and the mortality risk associated with each, Port el al.extrapolated to the US haemodialysis population for a
5-year period to quantify potential life-years gained [2].
Projections were obtained by computing the differ-
ence in the area under the 5-year survival curve be-
tween the general survival of haemodialysis patients
based on the actual mortality rate and the estimated
Combe et al. BMC Nephrology           (2019) 20:81 Page 8 of 12survival if patients outside targets were brought into
target range on the six modifiable factors based. The
projected total haemodialysis patient-years summed
over the 5 years of the analysis period PY is defined as.
PY = [(N0/L) * FD] + [(N1/L) * (t–(FD/L))] (Eq. 1).
where t is the total time period in years, FD the
fraction still on dialysis at t, L the annual rate of
haemodialysis patients lost from the haemodialysis
population due to death or transfer to transplantation
or peritoneal dialysis, N0 the number of patients preva-
lent at the start of the 5-year time interval, and N1 the
number of incident patients entering the haemodialysis
population during each year. PY is calculated for status
quo (PY0), where none of the patients outside the target
range are brought into compliance; for each modifi-
able factor i assuming all patients are brought into
compliance (PYi where i = Kt/V, phosphate, Hb, inter-
dialytic weight gain, albumin, AVF/graft); and for the
condition that all patients are brought into compliance
on all six factors (PYa).
From Eq. 1, we estimated the potential patient-years
gained over the 5-year time interval ΔPY5, for a given
modifiable factor and aggregated across all six factors,
as the difference between PY0 (the projected total
patient-years summed over 5 years) and the corre-
sponding PYi for the ith factor or PYa for the six fac-
tors aggregated; or.
ΔPY5,i = PY0 - PYi (Eq. 2).
and
ΔPY5,a = PY0 - PYa (Eq. 3).Ethics
The MONITOR-CKD5 study protocol was approved
by the ethical review committees of participating cen-
tres in accordance with national laws and regulations.
Written informed consent was obtained from all par-
ticipating patients.
Consort
N/A; this is not a clinical trial but a simulation study.
Results
Patients
A total of 2086 patients were enrolled yielding an evalu-
able enrolment sample of 2023 patients. Details of patient
enrolment and disposition have been reported elsewhere
[26] as have been centre-level and interim patient-level re-
sults [27]. Most patients (40.6%) were treated in Germany,
followed by Romania (18.6%) and Italy (15.3%), accounting
together for 74.4% of the study population. The sample
was predominantly male (59.3%), virtually completely
Caucasian (96.2%), with median age of 68 years (range
20–93). Median time on dialysis was 2.1 years (range 0–35). Most patients (82.5%) had been treated with another
ESA at enrolment, therefore can be considered in the
maintenance phase of renal anaemia management, and
were switched to Binocrit®. Mean (±SD) Hb at enrolment
was 11.09(±1.14)g/dL and 68.0% of patients had Hb values
in the 10-12 g/dL range.
In terms of the six modifiable factors, as can be calcu-
lated from Tables 2, 82.9% were within target range for
Kt/V (≥1.2), 61.5% had adequate phosphate control
(serum phosphate ≤5.5mg/dL), 86.0% had Hb ≥ 10 g/dL,
92.2% had interdialytic weight gain ≤5.7, 43.2% had partial
correction of serum albumin (≥4.0 g/dL), and 83.4% had
vascular access via either an arteriovenous fistula or graft.Estimated Patient Life-Years Gained
Table 4 summarizes the patient life-years gained over
five years, estimated per Eqs. 1 through 3 above, if re-
spectively an optimal 100% (or suboptimal 50%) of
patients falling outside of the recommended target
range on the six modifiable practices were brought into
compliance. Results are reported for each modifiable
factor separately, as well as for all 6 factors combined.
The baseline for the 10 MONITOR-CKD5 countries is
the estimated 303,517 haemodialysis patients for 2017.
This baseline is adjusted upward for the estimated
66,597 incident cases added over the 5-year period, ad-
justed downward for the variable annual death rate in
general and associated with compliance with each fac-
tor, and further adjusted downward for the fixed annual
loss rate to peritoneal dialysis or transplant.
The estimated potential patient-years gained over the
5-year period at status quo (PY0) is 1,563,221. At the singu-
lar modifiable factor level, bringing all patients into Kt/V
compliance yields 9319 additional patient-years over PY0
(for a total of 1,572,540); into phosphate compliance an add-
itional 22,052 patient-years (1,585,273); into Hb compliance
an additional 12,826 patient-years (1,576,047); into interdia-
lytic weight gain compliance an additional 7222 patient-
years (1,570,443); into albumin compliance an additional
92,344 patient-years (1,655,565); and into vascular access
compliance an additional 21,746 patient-years (1,584,967).
On the aggregate, bringing all patients into compliance on
all six modifiable factors results in an incremental gain of
97,428 patient-years for a total of 1,660,650 patient-years
(note that years gained if all 6 factors in target range is less
than the sum of the years gained on the 6 individual factors
since the modifiable practices are not mutually exclusive; i.e.
patients can be outside target range on ≥1 factor).Discussion
Using as baseline the estimated 303,517 haemodialysis pa-
tients estimated to be alive in 2017 in the 10 European
countries that participated in the MONITOR-CKD5
Table 4 Project patient-years gained based on relative risk for compliance with recommended targets (over 5 years)
Measure Current
statistics
Kt/V≥
1.2
Phosphate≤
5.5 mg/dL
Hb≥ 10
g/dL
IDWG≤
5.7%
Albumin ≥
4.0 g/dl
AVF or graft
v. catheter
All 6 Factors
Annual death rate 0.150 1 0.1467 2 0.1423 2 0.1455 2 0.1475 2 0.1189 2 0.1424 2 0.1173 2
Annual rate of
other loss3
0.053 0.053 0.053 0.053 0.053 0.053 0.053 0.053
L (Total loss rate) 0.203 0.200 0.195 0.199 0.200 0.172 0.195 0.170
T 5 5 5 5 5 5 5 5
N0
4 303,517 303,517 303,517 303,517 303,517 303,517 303,517 303,517
N1
5 66,597 66,597 66,597 66,597 66,597 66,597 66,597 66,597
FD 0.63760 0.63164 0.62343 0.62938 0.63298 0.57668 0.62363 0.57321
PY 1,563,221 1,572,540 1,585,273 1,576,047 1,570,443 1,655,565 1,584,967 1,660,650
Potential patient
years gained
if 100% brought within
target
9319 22,052 12,826 7222 92,344 21,746 97,4296
if 50% brought within
target7
4501 10,651 6195 3488 44,601 10,503 47,057
Hb haemoglobin, IDWG inter-dialytic weight gain, AVF arterio-venous fistula, L annual rate of US haemodialysis patients lost from the haemodialysis population
due to death or transfer to transplantation or peritoneal dialysis, t total time period, N0 number of patients prevalent at the start of the 5-year time interval, N1
number of incident patients entering the haemodialysis patient population during each year, FD fraction still on dialysis at time t, PY projected total haemodialysis
patient years summed over the 5 years of the analysis period
1 From ERA-EDTA Registry: Annual Report 2014. Table B.6.7.a. Unadjusted 1-year survival (cohort 2008–2012): incident dialysis patients (from day 91).
2 Mortality rate of pts. inside range = overall mortality / ((% of patients outside range * RR) + % of patients in range)
3 Other loss to peritoneal dialysis or transplant assumed to be 5.3%
4 N0 assumed to be 303,517 based upon population estimates for countries participating in MONITOR-CKD5 [Table 3]
5 N1 assumed to be 66,597 based upon population estimates for countries participating in MONITOR-CKD5 [Table 3]
6 Patient-years gained if all 6 factors in target range is less than the sum of the years gained on the 6 individual factors since the modifiable practices are not
mutually exclusive (i.e. patients can be outside target range on ≥1 factor)
7 Adjusted to 0.4830 of potential years gained if 100% brought within target (i.e. not .50, due to results of sensitivity analysis; personal communication with Arbor Research)
Combe et al. BMC Nephrology           (2019) 20:81 Page 9 of 12study, and adjusting this upward for growth in this patient
population and downward for mortality and transition to
peritoneal dialysis or transplantation, we projected that
the 5-year period starting in 2017 would yield a net total
of 1,563,221 patient-years under the haemodialysis prac-
tice patterns observed in the study. However, as the
DOPPS investigators have shown for several countries [2,
13–16], mortality in haemodialysis patients could poten-
tially be reduced and life expectancy increased by focusing
on six modifiable factors: dialysis quality (Kt/V), managing
phosphate, haemoglobin, and albumin levels, reducing
interdialytic weight gain (or, alternately managing cal-
cium), and minimizing catheter use for vascular access.
If all haemodialysis patients in the 10 MONITOR-CKD5
countries were brought into the target range of these six
modifiable practice patterns, an additional 97,429 patient
life-years would hypothetically be gained over the 5-year
period starting in 2017. This corresponds to a 6.2% increase
in 5-year survival. In comparison, the corresponding rates
from the country-specific DOPPS analyses of the modifi-
able practices are, in ascending order, 8.2% for the US,
13.1% for France, 14.7% for Spain, 17.8% for Sweden, and
22.5% for Belgium [2, 13–16]. The differences in rates may
be due to sample size. However, considering that these
simulation analyses cover a time span of approximately 15years, this variation in rates may also suggest significant im-
provements having been achieved in haemodialysis care
over time [28]. Though we chose not to perform country-
specific analyses, with collectively 25.3% of MONITOR-
CKD5 patients being treated in Central and Eastern
European countries, our lower rate in life-years gained un-
derscores the advances in the quality of haemodialysis care
made across all European regions.
This is also evident from the loss rates used in the
various analyses. Consistent with their time period and
country, Port et al. [2] assumed a 24.0% annual death
rate and 6.5% annual rate of other loss (transition or
peritoneal analysis or transplantation), for a total loss
rate of 30.5%. In the four country-specific DOPPS ana-
lyses [13–16], the annual death rates ranged from 17.1
to 24.3%, the annual other loss rates from a gain of 2.1%
to a loss of 5.3%, for total loss rates between 17.0 and
27.4% In our ten-country European analysis, these rates
were 15.0% (death-related), 5.3% (other), and 20.3%
(total).
With the historical trends of fewer patients outside of
the recommended range on each of the modifiable
practices and decreasing mortality rates in dialysis popu-
lations, there is a diminishing opportunity for further
improvement and, hence, smaller gains in potential life
Combe et al. BMC Nephrology           (2019) 20:81 Page 10 of 12years. Yet, there is still room for improvement. While
the percentage of patients out of range have decreased
across all six modifiable practices, only 15% of patients
in the MONITOR-CKD5 study were in range on all six.
The historical differences are also evident at the level
of the individual practice patterns. In the Port et al. [2]
analysis, reducing catheter use was associated with the
greatest gain in patient life-years (with the highest po-
tential gains in the USA), followed by increasing serum
albumin levels (a measure of nutritional status and in-
flammation), and phosphate control. In our analysis, the
greatest gains in theoretical patient life-years were
achieved by targeting patient’s serum albumin level
followed, remotely, by phosphate control and vascular
access. In the country-specific DOPPS analyses (which
did not include interdialytic weight gain but serum cal-
cium level instead), albumin levels and catheter use were
the modifiable factors that prevailed in impact, followed
by calcium levels and, variably, phosphate and Hb levels.
Despite these differences in rates, all analyses converged
on the importance of bringing albumin levels into target
range, assuring vascular access by means of fistula or graft,
and mineral control. That dialysis quality contributed only
modestly to survival in all analyses may reflect the long-
standing acceptance of the Kt/V ≥ 1.2 standard. One not-
able challenge for clinicians is that while serum albumin
exerts the most influence on mortality in these models in
terms of relative risk, it is perhaps the most resistant of
the six practices to therapeutic intervention, since it is
linked to different factors, mainly inflammation and nutri-
tional status [29].
Mortality risks attributable to the six modifiable prac-
tice patterns have not been systematically evaluated in
randomized controlled trials (RCT); though a RCT of an
established practice such as dialysis quality of Kt/V ≥ 1.2
versus < 1.2 would be ethically untestable. Hence, esti-
mating preventable mortality and associated life-years
gained as a function of modifiable practices may be ap-
propriate as secondary endpoints in randomized trials.
Further, the role of patient adherence, in particular to
dietary restrictions, phosphate binders, and dialysis regi-
men, should be examined in future studies [30–32].
Our analyses have limitations. Like DOPPS,
MONITOR-CKD5 is a non-controlled study. The use
of patient-level versus facility-level data for catheter
use may introduce treatment-by-indication bias especially
in terms of patient age, comorbid conditions, and disease
severity. The adjusted mortality risk associated with
patient-level vascular access data utilized in our study [21]
reduced such confounding but some residual bias cannot
be excluded. Countries in MONITOR-CKD5 differed in
some of the modifiable practices MONITOR-CKD5 [28].
The estimation of life-years gained using the
MONITOR-CKD5 aggregate sample may conceal specificcountries where opportunities for larger gains exist. Not
being part of the ERA-EDTA Registry, national reports
were used for Germany and Italy. The MONITOR-CKD5
patient population was virtually Caucasian with minimal
racial/ethnic variation.
Conclusions
Replicating and extending the DOPPS analyses [2, 13–16]
to the population in MONITOR-CKD5, we estimated in
this hypothetical simulation that bringing all haemodialy-
sis patients of the countries included in this study within
the target range of six modifiable practices would yield a
6.2% increase in patient life-years over 5 years. An add-
itional 97,429 life-years might be gained if, in descending
order of survival impact, haemodialysis patients could be
maintained at albumin levels ≥4.0 g/dL and phosphate
levels ≤5.5mg/dL, have vascular access by means of fistula
or graft, have haemoglobin maintained at ≥10 g/dL, re-
ceive dialysis at Kt/V ≥ 1.2, and have their interdialytic
weight gain limited to ≤5.7%. It is reassuring that com-
pared to the original DOPPS papers, potential gains linked
to quality improvement have decreased, reflecting better
achievement of recommended therapeutic goals.
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